Moderna

Covid-19

Merck sells stake in Moderna as vaccine gets FDA review

Merck sold its direct equity investment in Moderna during the first half of the fourth quarter.
Small is better for vaccine shares - THE EDGE SINGAPORE

Covid-19

Small is better for vaccine shares

Big vaccine news makes little difference to pharma giant shares.
Global economic recovery will be stronger than expected - THE EDGE SINGAPORE

Tong's Portfolio

Global economic recovery will be stronger than expected

Amid all the grim Covid-19 headlines, stock prices have continued to move higher.
Pfizer, BioNTech plan filing as vaccine proves 95% effective - THE EDGE SINGAPORE

Covid-19

Pfizer, BioNTech plan filing as vaccine proves 95% effective

A third contender, from AstraZeneca and the University of Oxford, is expected to release trial results in the coming days.
Moderna says Covid-19 vaccine is 94.5% effective in a preliminary analysis - THE EDGE SINGAPORE

Covid-19

Moderna says Covid-19 vaccine is 94.5% effective in a preliminary analysis

A preliminary analysis of data from more than 30,000 volunteers showed Moderna’s vaccine prevented virtually all symptomatic cases

Global review

China could well be the winner of the Covid-19 vaccine race

The race is on for the first Covid-19 vaccine, with five Chinese companies among the 10 that are in phase III studies.

Covid-19

Is a viable Covid-19 vaccine imminent?

Dr Mike Ryan, head of WHO’s emergencies program maintains that there is still a long way to go before a vaccine can be rolled out.

Covid-19

Lonza in manufacturing deal with Moderna for Covid-19 vaccine

The parties plan to produce up to 1 billion doses of the vaccine per year
  •  
×